838 results match your criteria Drug-Induced Bullous Disorders


Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.

Front Immunol 2021 16;12:665522. Epub 2021 Apr 16.

Molecular and Cell Biology Laboratory IDI-IRCCS, Rome, Italy.

COVID-19 is characterized by a severe pulmonary disease due to severe acute respiratory syndrome (SARS)-CoV-2 infection. For clinicians involved in the management of patients with chronic autoimmune diseases the risk linked to the conditions itself and to drug-induced immunosuppression during the COVID-19 pandemic is a major topic. Pemphigus is a rare autoimmune blistering disease (AIBD) of the skin and mucous membranes caused by autoantibodies to desmosomal components, desmoglein 1 and 3. Read More

View Article and Full-Text PDF

Drug induced oral erythema multiforme: Case report.

Medicine (Baltimore) 2021 Apr;100(17):e22387

Department of Prosthetic Dentistry, College of Dentistry, King Khalid University, Abha, Kingdom of Saudi Arabia.

Introduction: Drug induced oral erythema multiforme a rare clinical entity which involves only the lips and oral mucosa without skin involvement. These lesions are difficult in diagnosing with other oral ulcerative lesions with similar clinical manifestations.

Patient Concerns: This article presents 2 case reports of Oral erythema multiforme in which drugs were the precipitating factor. Read More

View Article and Full-Text PDF

Bronchiolitis obliterans following toxic epidermal necrolysis: a case report.

J Med Case Rep 2021 Mar 30;15(1):159. Epub 2021 Mar 30.

Institute of Medicine, Tribhuwan University, Kathmandu, Nepal.

Background: Toxic epidermal necrolysis (TEN) is a rare, acute and potentially fatal skin condition usually induced by drugs. Although much attention is focused on the life threatening acute cutaneous and sight threatening ocular manifestations of this disease, chronic pulmonary complications like bronchiolitis obliterans are occasionally encountered. However, little is known about its incidence, pathogenesis, clinical course and outcome in children recovering from TEN. Read More

View Article and Full-Text PDF

[DIAGNOSIS AND TREATMENT OF SEVERE DRUG ERUPTION].

Authors:
Hirohiko Sueki

Arerugi 2021;70(2):86-93

Department of Dermatology, Showa University School of Medicine.

View Article and Full-Text PDF

Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis.

J Am Acad Dermatol 2021 Jul 5;85(1):1-14. Epub 2021 Mar 5.

Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Subepithelial autoimmune blistering dermatoses are a group of rare skin disorders that are characterized by the disruption of the dermal-epidermal junction through the action of autoantibodies. The third article in this continuing medical education series explores the background, epidemiology, clinical features, and diagnostic criteria of each of the major subepithelial autoimmune blistering dermatoses, including bullous pemphigoid, pemphigoid gestationis, lichen planus pemphigoides, mucous membrane pemphigoid, linear IgA bullous dermatosis, and dermatitis herpetiformis. Read More

View Article and Full-Text PDF

Severe cutaneous adverse reaction associated with antiseizure medications: Diagnosis, management, and prevention.

Epilepsy Behav 2021 04 25;117:107844. Epub 2021 Feb 25.

Department of Pharmacology & Toxicology, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.

Severe cutaneous adverse reactions (SCARs) are potentially life-threatening, with considerable morbidity and mortality. They are nonimmediate hypersensitivity reactions that occur in specifically predisposed patients with delayed T-cell-mediated hypersensitivity reaction. Antiseizure medications (ASMs) are among the drugs that can induce SCAR. Read More

View Article and Full-Text PDF

Erythema multiforme: integrating the superfluous diagnosis to a veracious conclusion (case report).

Pan Afr Med J 2020 6;37:129. Epub 2020 Oct 6.

Department of Oral Medicine and Radiology, SVS Institute of Dental Sciences, Mahabubnagar-509002, Telangana, India.

Erythema multiforme (EM) is an acute, self-limiting hypersensitivity reaction that ranges from a mild cutaneous, exanthematous variant with minimal oral involvement to a progressive fulminating severe variant with extensive mucocutaneous epithelial necrosis (SJS & TEN). Knowing the etiological spectrum is the key for management in EM where sometimes leads to mortality. There are no specific diagnostic tests for EM, diagnosis is mainly clinically supported. Read More

View Article and Full-Text PDF
January 2021

Doxycycline-Associated Dual Cutaneous Adverse Reaction to the Drug (CARD): Case Report of Concurrent Photosensitivity and Morbilliform Exanthem to Doxycycline.

Cureus 2020 Nov 18;12(11):e11546. Epub 2020 Nov 18.

Dermatology, San Diego Family Dermatology, National City, USA.

Antibiotics have been observed to cause drug-induced reactions. These can include a cutaneous adverse reaction to the drug (CARD) such as photosensitivity. A 51-year-old woman initiated doxycycline monohydrate for rosacea. Read More

View Article and Full-Text PDF
November 2020

Non infective bullous lesions: a diagnostic challenge in a minimally equipped centre- based solely on microscopic findings.

Afr Health Sci 2020 Jun;20(2):885-890

Pandit Deendayal Upadhyay Medical College.

Vesicobullous lesions of skin may occur in different forms of dermatosis, which include various inflammatory, infective, autoimmune, drug induced as well as genetic conditions. Autoimmune bullous lesions, may be fatal if not treated with appropriate agents. Bearing in mind, the morbidity of these diseases, it is important to establish a firm diagnosis. Read More

View Article and Full-Text PDF

Real-time clinical note monitoring to detect conditions for rapid follow-up: A case study of clinical trial enrollment in drug-induced torsades de pointes and Stevens-Johnson syndrome.

J Am Med Inform Assoc 2021 01;28(1):126-131

Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Identifying acute events as they occur is challenging in large hospital systems. Here, we describe an automated method to detect 2 rare adverse drug events (ADEs), drug-induced torsades de pointes and Stevens-Johnson syndrome and toxic epidermal necrolysis, in near real time for participant recruitment into prospective clinical studies. A text processing system searched clinical notes from the electronic health record (EHR) for relevant keywords and alerted study personnel via email of potential patients for chart review or in-person evaluation. Read More

View Article and Full-Text PDF
January 2021

Erythroderma: A clinicopathological study of 47 cases from 2018 to 2020.

Dermatol Ther 2020 11 10;33(6):e14342. Epub 2020 Oct 10.

Department of Dermatology and Venereology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Erythroderma, or exfoliative dermatitis, is an inflammatory disorder characterized by erythema and scaling, affecting most of the skin surface. It may be a result of many different causes such as previous dermatoses (psoriasis, eczema, atopic dermatitis [AD], pityriasis rubra pilaris, and pemphigus foliaceous), drug reactions, malignancies (mycosis fungoides [MF], Sézary syndrome, adult T cell leukemia/lymphoma), infections, and idiopathic disorders. Regardless of the etiology, the clinical appearance of erythroderma is similar in all patients. Read More

View Article and Full-Text PDF
November 2020

Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.

Dermatol Online J 2020 Aug 15;26(8). Epub 2020 Aug 15.

Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne.

Nivolumab and ipilimumab are immune checkpoint inhibitors (ICIs) used in the management of advanced malignancies including malignant melanoma. Although several cutaneous adverse events have been reported with these immunotherapy agents, toxic epidermal necrolysis (TEN) secondary to ICIs is rare. We report a 67-year-old man with TEN occurring during nivolumab and ipilimumab co-therapy and review published cases to highlight the challenges in recognizing and managing these patients. Read More

View Article and Full-Text PDF

Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept.

J Dermatol 2020 Nov 15;47(11):1236-1248. Epub 2020 Sep 15.

Department of Burns and Plastic Surgery, Institution shared with University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Toxic epidermal necrolysis (TEN) represents a rare drug-induced autoimmune reaction with delayed-type hypersensitivity that initiates the process of developing massive keratinocyte apoptosis, dominantly in the dermoepidermal junction. Although the etiopathophysiology has not yet been fully elucidated, the binding of Fas ligand (FasL, CD95L) to the Fas receptor (CD95) was shown to play a key role in the induction of apoptosis in this syndrome. The knowledge of the role of immunoglobulin G (IgG) in inhibition of Fas-mediated apoptosis contributed to the introduction of i. Read More

View Article and Full-Text PDF
November 2020

Pediatric SJS-TEN: Where are we now?

F1000Res 2020 13;9. Epub 2020 Aug 13.

Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Hospitals and Clinics, Kansas City, MO, USA.

Stevens-Johnson syndrome and toxic epidermal necrolysis are rare severe blistering skin reactions triggered by medications or infections. Over the last 5 to 10 years, a number of important publications have advanced understanding of these diseases and their response to treatment. Importantly, a subset of patients with disease triggered by infection has been identified as having Mycoplasma pneumoniae-induced rash and mucositis, suggesting a reconsideration of the diagnostic paradigm. Read More

View Article and Full-Text PDF
October 2020

Drug-induced Bullous Pemphigoid and Lupus Erythematosus Occurring under Anti-TNF-α and IL-6 Therapy in a Patient with Rheumatoid Arthritis.

Intern Med 2020 Oct 7;59(20):2611-2618. Epub 2020 Jul 7.

Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Japan.

A 65-year-old Japanese woman, who was diagnosed with rheumatoid arthritis and Sjögren's syndrome with various autoantibodies including anti-DNA antibody, developed bullous pemphigoid (BP) and hematological abnormalities like lupus erythematosus after adalimumab therapy. The discontinuation of adalimumab resolved those disorders but polyarthritis thereafter relapsed. The introduction of abatacept was not effective, but tocilizumab was found to be effective for polyarthritis, however, thereafter both bullous disease and severe pancytopenia developed. Read More

View Article and Full-Text PDF
October 2020

A case of drug-induced bullous pemphigoid associated with teriflunomide: A patient with relapsing multiple sclerosis.

Mult Scler Relat Disord 2020 Aug 15;43:102157. Epub 2020 May 15.

Hacettepe University, Department of Neurology, Hacettepe, 06230, Ankara, Turkey.

Background: There aren't many reported skin changes associated with teriflunomide use in patients with multiple sclerosis (MS) mm Only one life-threatening gross skin change has been reported so far; a patient with toxic epidermal necrolysis. There are also a few case reports about cutaneous adverse effects of teriflunomide, such as eczema, rash and palmar pustular psoriasis.

Methods: We herein report the first case of bullous drug reaction in a patient receiving teriflunomide treatment. Read More

View Article and Full-Text PDF

Response to: "Missed induced bullous pemphigoid: When the anamnesis is the cure," a comment on "Missed drug-induced bullous pemphigoid leads to longer immunosuppression than recognized cases: A 9-year retrospective review".

J Am Acad Dermatol 2020 09 19;83(3):e223-e224. Epub 2020 May 19.

Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article and Full-Text PDF
September 2020

Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN).

J Eur Acad Dermatol Venereol 2020 Sep 15;34(9):1957-1971. Epub 2020 May 15.

Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands.

The severe cutaneous adverse reaction epidermal necrolysis (EN) which includes toxic epidermal necrolysis and the milder Stevens-Johnson syndrome is characterized by epidermal loss due to massive keratinocyte apoptosis and/or necroptosis. EN is often caused by a drug mediating a specific TCR-HLA interaction via the (pro)hapten, pharmacological interaction or altered peptide loading mechanism involving a self-peptide presented by keratinocytes. (Memory) CD8 + T cells are activated and exhibit cytotoxicity against keratinocytes via the perforin/granzyme B and granulysin pathway and Fas/FasL interaction. Read More

View Article and Full-Text PDF
September 2020

BRAF inhibitor and hairy cell leukemia-related transient acantholytic dermatosis.

Dermatol Online J 2020 Feb 15;26(2). Epub 2020 Feb 15.

Department of Dermatology, University of New Mexico, School of Medicine, Albuquerque, NM.

Grover disease (GD) is an acquired, nonfamilial, nonimmune mediated, transient or persistent acantholytic dermatosis. Herein, we present a 72-year-old man who had clinical and histopathologic findings of GD following two weeks of treatment with vemurafenib without MEK inhibitor. The patient was successfully treated with topical emollients and a high-potency corticosteroid. Read More

View Article and Full-Text PDF
February 2020

Retrospective review of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution.

Pediatr Dermatol 2020 May 14;37(3):461-466. Epub 2020 Feb 14.

Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Background/objectives: Stevens-Johnson syndrome and toxic epidermal necrolysis represent important sources of potential mortality and morbidity in children. There is a need for more clinical data in this population to determine whether specific treatments preferentially improve outcomes.

Methods: This was a single-center retrospective review of children admitted with drug-induced Stevens-Johnson syndrome, toxic epidermal necrolysis or Stevens-Johnson syndrome/toxic epidermal necrolysis overlap at a tertiary care pediatric institution in North America from 2008 to 2018. Read More

View Article and Full-Text PDF

Bullous Drug Reactions.

Authors:
Maja Mockenhaupt

Acta Derm Venereol 2020 02 12;100(5):adv00057. Epub 2020 Feb 12.

Dokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center - University of Freiburg, Hauptstrasse 7, DE-79104 Freiburg, Germany.

Bullous drug eruptions are infrequent, but because they pose a challenge both to affected patients and to treating physicians they are considered to be the most severe cutaneous adverse reactions (SCAR). It is important to recognize these conditions and to differentiate them from other clinical entities involving blister formation. There may be early signs and symptoms that indicate a severe bullous drug eruption even before blisters and erosions of the skin and mucous membranes become obvious. Read More

View Article and Full-Text PDF
February 2020

The interferon-γ-induced protein 10/CXCR3 axis is associated with human herpesvirus-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms.

Br J Dermatol 2020 11 20;183(5):909-919. Epub 2020 Mar 20.

Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a condition caused by a drug-induced immune response. Previous reports have found that CXCL10, also known as interferon-γ-induced protein (IP)-10, may participate in the pathogenesis of cutaneous adverse drug reactions. However, the exact role of IP-10 in DRESS and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) has remained unknown. Read More

View Article and Full-Text PDF
November 2020

Missed drug-induced bullous pemphigoid leads to longer immunosuppression than recognized cases: A 9-year retrospective review.

J Am Acad Dermatol 2020 05 9;82(5):1255-1258. Epub 2020 Jan 9.

Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article and Full-Text PDF

Linear IgA dermatosis of the childhood-Report of an amoxicillin-induced case.

Dermatol Ther 2020 01 4;33(1):e13173. Epub 2019 Dec 4.

Institute of Pathology, School of Medicine, University of Belgrade, Belgrade, Serbia.

Linear IgA dermatosis (LAD) is a rare autoimmune disorder in children. A 9-year-old boy was presented with blisters on the intact skin (face, body, arms, hands, soles, perigenital and perianal area) after amoxicillin treatment. Systemic corticosteroids and dapsone treatment for 6 weeks was successful. Read More

View Article and Full-Text PDF
January 2020

Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting.

Seizure 2019 Nov 3;72:61-70. Epub 2019 Jul 3.

St George's University Medical School, United Kingdom; St George's Univ. Hospital NHS Foundation Trust, United Kingdom.

Adverse cutaneous reactions caused by mostly aromatic antiepileptic drugs (AED) affect 50.000 people a year in the United Kingdom (UK; incidence 75.7/100. Read More

View Article and Full-Text PDF
November 2019

Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions.

Curr Pharm Des 2019 ;25(36):3840-3854

Department of Pediatric Allergy and Immunology, University of Health Sciences, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, Ankara, Turkey.

Drug hypersensitivity reactions are clinically heterogenous ranging from mild to severe. Most drug hypersensitivity reactions are accompanied by cutaneous manifestations. Fever, mucous membrane involvement, large blisters, facial oedema, pustulosis and visceral involvement are clinical features that lead to suspicion of severe adverse drug reactions. Read More

View Article and Full-Text PDF

Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach.

Curr Pharm Des 2019 ;25(36):3855-3871

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

Idiosyncratic drug-induced liver injury (DILI) occasionally occurs in the setting of severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS). This strengthens the proposed immunologic mechanism associated with this adverse reaction. DRESS exhibits the most common association with DILI. Read More

View Article and Full-Text PDF

Epidemiology and Risk Factors for Severe Delayed Drug Hypersensitivity Reactions.

Curr Pharm Des 2019 ;25(36):3799-3812

Allergy and Clinical Immunology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.

Severe delayed drug hypersensitivity reactions comprise different clinical entities and can involve different immune-mediated mechanisms. Common examples are severe cutaneous adverse reactions and druginduced internal organ injuries. The incidence of such reactions is overall low but seems to be on the rise reaching numbers as high as 9 per million individuals-years in the case of SJS/TEN and DRESS. Read More

View Article and Full-Text PDF

An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions.

Curr Pharm Des 2019 ;25(36):3881-3901

Department of Pediatric Allergy and Immunology, Mersin University, Faculty of Medicine, Mersin, Turkey.

Severe cutaneous drug hypersensitivity reactions involve of different mechanisms , some of which are life-threatening, such as Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, generalized bullous fixed drug eruptions, serum sickness and serum sickness-like reaction and drug-induced vasculitis. These reactions may have substantial morbidity and mortality. In the past years, successive studies have provided new evidence regarding the pathogenesis of some of these severe reactions and revealed that underlying mechanisms are highly variable. Read More

View Article and Full-Text PDF

[Drug-induced toxic epidermal necrolysis with secondary aspergillus fumigatus infection: a case report].

Beijing Da Xue Xue Bao Yi Xue Ban 2019 Oct;51(5):977-980

Department of Dermatological, Peking University People's Hospital, Beijing 100044, China.

Among the various drug induced dermatological entities toxic epidermalnecrolysis (TEN) and Stevens-Johnson syndrome (SJS) occupy a primary place in terms of mortality. Toxic epidermal necrolysis also known as Lyell's syndrome was first described by Lyell in 1956. Drugs are by far the most common cause of toxic epidermal necrolysis, in which large sheets of skin are lost from the body surface making redundant the barrier function of the skin, with its resultant complications. Read More

View Article and Full-Text PDF
October 2019